Botox-maker Allergan has today reported adjusted profit that beat analysts' estimates, and raised its 2017 forecast to include its $2.48 billion acquisition of Zeltiq Aesthetics.
Excluding items, Dublin-based Allergan earned $3.35 per share, helped by sales of its newer medicines and key products, including Botox.
Analysts on average expected earnings of $3.30 per share, according to Thomson Reuters.
Allergan in February agreed to buy Zeltiq, a device that is designed to freeze fat away, adding to its line-up of aesthetic products.
The company raised its net revenue forecast to $15.8 billion-$16 billion, from $15.5 billion-$15.8 billion.
Net loss attributable to ordinary shareholders was $2.63 billion, or $7.86 per share, in the first quarter ended March 31, compared with a profit of $186.1m, or 47 cents per share, a year earlier.
The company reported a first-quarter loss mainly due to amortisation, research and development related charges and in-process research and development impairments.
Amortisation expenses from continuing operations was $1.74 billion, compared with $1.59 billion in the year-ago quarter.
Net revenue for the acquisitive company rose to $3.57 billion from $3.40 billion.
